Furthermore, it provides the first biological justification for use of MRB in a non-primary hyperaldosteronism population by the analysis of the BP response to different treatments with respect to plasma renin levels, indicating that sodium retention may play an important role in TRH. The gene discussed is REN; the disease is Primary hyperaldosteronism.